Video

Dr. Tolaney on the ATEMPT Trial for HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

This trial investigated patients with stage I HER2-positive disease following the APT trial, states Tolaney. The aim of the study was to determine if using T-DM1 (ado-trastuzumab emtansine; Kadcyla) is a beneficial approach.

The trial randomized patients to a year of T-DM1 or paclitaxel and trastuzumab (Herceptin). It was designed to compare the clinically relevant toxicities seen between the 2 arms and establish a 3-year disease-free survival in the T-DM1 arm. The trial has completed accrual and results are expected 2019, explains Tolaney.

Related Videos
Shaji Kumar, MD
Kevin Kalinsky, MD, MS
Guru P. Sonpavde, MD
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD
Suneel Kamath, MD
Kathleen N. Moore, MD, MS
Shaji Kumar, MD